Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Johnson & Johnson MedTech Automated Impella Controller

FDA details new risk with Johnson & Johnson heart pump controllers after patient’s death

This latest alert was put in place after Johnson & Johnson MedTech learned that some of its Automated Impella Controllers were built to the wrong specifications, impacting their ability to function. Affected devices should not be used going forward.

The U.S. Food and Drug Administration (FDA) updated the Breakthrough Device Program designations data this week, which now includes 1,176 Breakthrough Device designations, of which 160 have gained market clearance. Cardiovascular devices lead these with 243 devices, the highest number out of all other clinical categories. This includes 16 new cardiovascular devices cleared in the past year.

Cardiovascular device approvals continue to lead the FDA's Breakthrough Device Program

Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.

Thumbnail

FDA announces Class I recalls for heart pump accessories due to safety risk

Abbott has warned healthcare providers about a new issue with the mobile power units of certain HeartMate 3 LVADs. 

Thumbnail

Palliative care plays an essential role in heart failure care

New HFSA recommendations highlight the importance of integrating palliative care into the day-to-day care of heart failure patients.

Wildfire pollution image. Photo courtesy of the American Heart Association.

Air purifiers may reduce cardiovascular risks from pollution and wildfires

Multiple studies in recent years have linked poor air quality to significant cardiac risks. Air filters, however, have shown potential to help combat these risks.

The Ventric Health Vivio AI system screens for elevated left ventricular end-diastolic pressure, or filling pressure (LVEDP) quickly with a a five-minute, noninvasive test using a blood pressure cuff, single-lead Bluetooth-enabled ECG, and proprietary algorithm. This can be performed in a single primary care office visit.

Algorithm brings early heart failure screening to primary care office visits

Most patients are first diagnosed with heart failure in an emergency room or hospital, when their symptoms are already severe. This advanced algorithm could change all that by opening up screening to many more patients. 

ESC Congress 2022 European Society of Cardiology

The most anticipated trials at ESC 2025

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Displaying 1 - 8 of 734
Design by Adaptive Theme